Research Article
BibTex RIS Cite
Year 2019, Volume: 66 Issue: 4, 385 - 389, 09.09.2019
https://doi.org/10.33988/auvfd.552122

Abstract

References

  • 1. Albaaj F, Hutchinson AJ (2003): Hyperphosphatemia in renal failure, causes, consequences and current management. Drugs, 63, 577–96.
  • 2. Altıntaş A, Üren N, Pekcan M, et al (2006): Kronik böbrek yetmezliği belirtileri gösteren kedilerde biyokimyasal ve hematolojik değişiklikler. Ankara Univ Vet Fak Derg, 53, 97-102.
  • 3. Barber PJ, Elliott J (1995): Feline chronic renal failure: calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract, 39, 108–11.
  • 4. Bertazzolo W, Toscani L, Calcaterra S, et al (2003): Clinicopathological findings in five cats with paw calcification. JMFS, 5, 11-17.
  • 5. Block GA, Hulbert-Shearon TE, Levin NW, et al (1998): Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 31, 607–17.
  • 6. Bohmer E, Hanichen T, Lohss E (1991): Cutaneous calcinosis of the foodpads in a cat. Tierarztliche Praxis, 19, 88–95.
  • 7. Boyd LM, Langston C, Thompson K, et al (2008): Survival in cats with naturally occurring chronic kidney disease (2000 –2002). J Vet Intern Med, 22, 1111–1117.
  • 8. Börkü MK, Durgut R, Kurtdede A, et al (2000): Kronik böbrek yetmezligi belirtileri gösteren kedi ve köpeklerde klinik, laboratuvar ve patolojik bulgular. Ankara Univ Vet Fak Derg, 47, 288-289.
  • 9. Broek DHN, Chang YM, Elliott J, et al (2017): Chronic kidney disease in cats and the risk of total hypercalcemia. J Vet Intern Med, 31, 465–475.
  • 10. Chalhoub S, Langston C, Eatroff A (2011): Anemia of renal disease: what it is, what to do and what’s new. J Feline Med Surg, 13, 629–640.
  • 11. Cooks M, Lothrorp CD (1994): Serum erythropoietin concentrations measured by radioimmunoassay in normal, polycythernic, and anemic dogs and cats. J Vet Intern Med, 8, 18-25.
  • 12. Dibartola SP, Rutgers HC, Zack PM, et al (1987): Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973–1984). J Am Vet Med Assoc, 190, 1196–1202.
  • 13. Dibartola SP, Willard MD (2006): Disorders of phosphorous: hypophosphatemia and hyperphosphatemia. 195–209. In: SP Dibartola (Ed), Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. Elsevier, Missouri.
  • 14. Egenvall A, Nodtvedt A, Haggstrom J, et al (2009): Mortality of life-insured Swedish cats during 1999–2006: age, breed, sex, and diagnosis. J Vet Intern Med, 23, 1175–1183.
  • 15. Elliot J, Rawlings JM, Markwell PJ, et al (2000): Survival of cats with naturally occurring chronic renal failure. Effect of dietary management. J Small Anim Pract, 41, 235–242.
  • 16. Elliott J, Watson A (2014): Chronic kidney disease: International Renal Interest Society staging and management. 857–863. In: J Bonagura, D Twedt (Ed). Current Veterinary Therapy, Saunders-Elsevier, Louis.
  • 17. Elliotta J, Barber PJ (1998): Feline chronic renal failure: clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract, 39, 78-85.
  • 18. Ganesh SK, Stack AG, Levin NW, et al (2001): Association of elevated serum PO4, Ca x PO4 product, and para - thyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol, 12, 2131–138.
  • 19. Hamilton JB, Hamilton RS, Mestler GE (1969): Duration of life and causes of death in domestic cats: influence of sex, gonadectomy, and inbreeding. J Gerontol, 24, 427–437.
  • 20. Kestenbaum B, Sampson JN, Rudser KD, et al (2005): Serum phosphate levels and mortality risk among people with chronic kidney disease. Am Soc Nephrol, 16, 520-528.
  • 21. Kuwahara Y, Ohba Y, Kitoh K, et al (2006): Association of laboratory data and death within one month in cats with chronic renal failure. J Small Anim Pract, 47, 446–450.
  • 22. Lawson J, Elliott J, Wheeler-Jones C, et al (2015): Renal fibrosis in feline chronic kidney disease: known mediators and mechanisms of injury. Vet J, 203, 18–26.
  • 23. Lulich P, Osborne C, O'brıen T D, et al (1992): Feline renal failure: questions, answers. questions. Compendium, 14, 127-152.
  • 24. Lund EM, Armstrong PJ, Kirk CA, et al (1999): Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc, 214, 1336–1341.
  • 25. Peacock M (2010): Calcium metabolism in health and disease. Clin J Am Soc Nephrol, 5, 23–30.
  • 26. Polzin DJ (2011): Chronic kidney disease in small animals. Vet Clin North Am: Small Anim Pract, 41, 15–30.
  • 27. Schenck PA, Chew DJ (2008): Calcium: total or ionized? Vet Clin North Am: Small Anim Pract, 38, 497–502.

Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease

Year 2019, Volume: 66 Issue: 4, 385 - 389, 09.09.2019
https://doi.org/10.33988/auvfd.552122

Abstract

Chronic kidney disease
(CKD) and mineral disorders are one of the most common reasons of cats.
Alterations in mineral metabolism occur in early stage of CKD and increasing
the severity in advanced stages. In Turkey, although some clinical studies on
CKD in cats are available, no data concerning the clinical significance of
pretreatment Ca-P solubility product is present. The purpose of the current
study was to determine of Ca-P solubility product and its association with the
life quality of cats with CKD. Staging system for classifying cats with chronic
kidney disease was based on IRIS guideline. The following groups were occurred
based on serum creatinine (SCr) and urine specific gravity < 1035: Stage 2=
SCr 1.6 - 2.8 mg/dl; Stage 3= SCr 2.9 - 5.0 mg/dl; Stage 4= SCr > 5.0 mg/dl.
Solubility product (calcium x phosphorus) was also defined. Although calcium
levels were within reference ranges in groups, Ca-P product were above 72 mg2/dl2
in stage 3 and 4 cats. In conclusion, determination of pretreatment Ca-P solubility
product in cats with different stages of CKD could be useful to modify and
manage the life quality of cats with CKD.

References

  • 1. Albaaj F, Hutchinson AJ (2003): Hyperphosphatemia in renal failure, causes, consequences and current management. Drugs, 63, 577–96.
  • 2. Altıntaş A, Üren N, Pekcan M, et al (2006): Kronik böbrek yetmezliği belirtileri gösteren kedilerde biyokimyasal ve hematolojik değişiklikler. Ankara Univ Vet Fak Derg, 53, 97-102.
  • 3. Barber PJ, Elliott J (1995): Feline chronic renal failure: calcium homeostasis in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract, 39, 108–11.
  • 4. Bertazzolo W, Toscani L, Calcaterra S, et al (2003): Clinicopathological findings in five cats with paw calcification. JMFS, 5, 11-17.
  • 5. Block GA, Hulbert-Shearon TE, Levin NW, et al (1998): Association of serum phosphorous and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 31, 607–17.
  • 6. Bohmer E, Hanichen T, Lohss E (1991): Cutaneous calcinosis of the foodpads in a cat. Tierarztliche Praxis, 19, 88–95.
  • 7. Boyd LM, Langston C, Thompson K, et al (2008): Survival in cats with naturally occurring chronic kidney disease (2000 –2002). J Vet Intern Med, 22, 1111–1117.
  • 8. Börkü MK, Durgut R, Kurtdede A, et al (2000): Kronik böbrek yetmezligi belirtileri gösteren kedi ve köpeklerde klinik, laboratuvar ve patolojik bulgular. Ankara Univ Vet Fak Derg, 47, 288-289.
  • 9. Broek DHN, Chang YM, Elliott J, et al (2017): Chronic kidney disease in cats and the risk of total hypercalcemia. J Vet Intern Med, 31, 465–475.
  • 10. Chalhoub S, Langston C, Eatroff A (2011): Anemia of renal disease: what it is, what to do and what’s new. J Feline Med Surg, 13, 629–640.
  • 11. Cooks M, Lothrorp CD (1994): Serum erythropoietin concentrations measured by radioimmunoassay in normal, polycythernic, and anemic dogs and cats. J Vet Intern Med, 8, 18-25.
  • 12. Dibartola SP, Rutgers HC, Zack PM, et al (1987): Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973–1984). J Am Vet Med Assoc, 190, 1196–1202.
  • 13. Dibartola SP, Willard MD (2006): Disorders of phosphorous: hypophosphatemia and hyperphosphatemia. 195–209. In: SP Dibartola (Ed), Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice. Elsevier, Missouri.
  • 14. Egenvall A, Nodtvedt A, Haggstrom J, et al (2009): Mortality of life-insured Swedish cats during 1999–2006: age, breed, sex, and diagnosis. J Vet Intern Med, 23, 1175–1183.
  • 15. Elliot J, Rawlings JM, Markwell PJ, et al (2000): Survival of cats with naturally occurring chronic renal failure. Effect of dietary management. J Small Anim Pract, 41, 235–242.
  • 16. Elliott J, Watson A (2014): Chronic kidney disease: International Renal Interest Society staging and management. 857–863. In: J Bonagura, D Twedt (Ed). Current Veterinary Therapy, Saunders-Elsevier, Louis.
  • 17. Elliotta J, Barber PJ (1998): Feline chronic renal failure: clinical findings in 80 cases diagnosed between 1992 and 1995. J Small Anim Pract, 39, 78-85.
  • 18. Ganesh SK, Stack AG, Levin NW, et al (2001): Association of elevated serum PO4, Ca x PO4 product, and para - thyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol, 12, 2131–138.
  • 19. Hamilton JB, Hamilton RS, Mestler GE (1969): Duration of life and causes of death in domestic cats: influence of sex, gonadectomy, and inbreeding. J Gerontol, 24, 427–437.
  • 20. Kestenbaum B, Sampson JN, Rudser KD, et al (2005): Serum phosphate levels and mortality risk among people with chronic kidney disease. Am Soc Nephrol, 16, 520-528.
  • 21. Kuwahara Y, Ohba Y, Kitoh K, et al (2006): Association of laboratory data and death within one month in cats with chronic renal failure. J Small Anim Pract, 47, 446–450.
  • 22. Lawson J, Elliott J, Wheeler-Jones C, et al (2015): Renal fibrosis in feline chronic kidney disease: known mediators and mechanisms of injury. Vet J, 203, 18–26.
  • 23. Lulich P, Osborne C, O'brıen T D, et al (1992): Feline renal failure: questions, answers. questions. Compendium, 14, 127-152.
  • 24. Lund EM, Armstrong PJ, Kirk CA, et al (1999): Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. J Am Vet Med Assoc, 214, 1336–1341.
  • 25. Peacock M (2010): Calcium metabolism in health and disease. Clin J Am Soc Nephrol, 5, 23–30.
  • 26. Polzin DJ (2011): Chronic kidney disease in small animals. Vet Clin North Am: Small Anim Pract, 41, 15–30.
  • 27. Schenck PA, Chew DJ (2008): Calcium: total or ionized? Vet Clin North Am: Small Anim Pract, 38, 497–502.
There are 27 citations in total.

Details

Primary Language English
Subjects Veterinary Surgery
Journal Section Articles
Authors

Ekrem Çağatay Çolakoğlu 0000-0003-2789-035X

Hadi Alihosseini 0000-0001-8846-4827

Ali Evren Haydardedeoğlu 0000-0002-8473-0072

Publication Date September 9, 2019
Published in Issue Year 2019Volume: 66 Issue: 4

Cite

APA Çolakoğlu, E. Ç., Alihosseini, H., & Haydardedeoğlu, A. E. (2019). Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease. Ankara Üniversitesi Veteriner Fakültesi Dergisi, 66(4), 385-389. https://doi.org/10.33988/auvfd.552122
AMA Çolakoğlu EÇ, Alihosseini H, Haydardedeoğlu AE. Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease. Ankara Univ Vet Fak Derg. September 2019;66(4):385-389. doi:10.33988/auvfd.552122
Chicago Çolakoğlu, Ekrem Çağatay, Hadi Alihosseini, and Ali Evren Haydardedeoğlu. “Clinical Significance of Pretreatment Ca-P Solubility Product in 47 Cats With Chronic Kidney Disease”. Ankara Üniversitesi Veteriner Fakültesi Dergisi 66, no. 4 (September 2019): 385-89. https://doi.org/10.33988/auvfd.552122.
EndNote Çolakoğlu EÇ, Alihosseini H, Haydardedeoğlu AE (September 1, 2019) Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease. Ankara Üniversitesi Veteriner Fakültesi Dergisi 66 4 385–389.
IEEE E. Ç. Çolakoğlu, H. Alihosseini, and A. E. Haydardedeoğlu, “Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease”, Ankara Univ Vet Fak Derg, vol. 66, no. 4, pp. 385–389, 2019, doi: 10.33988/auvfd.552122.
ISNAD Çolakoğlu, Ekrem Çağatay et al. “Clinical Significance of Pretreatment Ca-P Solubility Product in 47 Cats With Chronic Kidney Disease”. Ankara Üniversitesi Veteriner Fakültesi Dergisi 66/4 (September 2019), 385-389. https://doi.org/10.33988/auvfd.552122.
JAMA Çolakoğlu EÇ, Alihosseini H, Haydardedeoğlu AE. Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease. Ankara Univ Vet Fak Derg. 2019;66:385–389.
MLA Çolakoğlu, Ekrem Çağatay et al. “Clinical Significance of Pretreatment Ca-P Solubility Product in 47 Cats With Chronic Kidney Disease”. Ankara Üniversitesi Veteriner Fakültesi Dergisi, vol. 66, no. 4, 2019, pp. 385-9, doi:10.33988/auvfd.552122.
Vancouver Çolakoğlu EÇ, Alihosseini H, Haydardedeoğlu AE. Clinical significance of pretreatment Ca-P solubility product in 47 cats with chronic kidney disease. Ankara Univ Vet Fak Derg. 2019;66(4):385-9.